| abstract |
The present invention relates to a non-viral gene-editing CRISPR nanocomposite, a method for producing the same. The non-viral gene-editing CRISPR nanocomposite according to the present invention has a size of several nanometers to several microns, can be delivered intracellularly without external physical stimulation, and is a gene by a non-viral pathway to the target gene of the cell. It can be useful for editing. As a result, when the CRISPR nanocomposite is used in animal model production, microbial engineering, cell engineering for disease treatment, or in vivo dosage form, it shows high intracellular delivery and gene editing efficiency, and causes non-specific editing, gene mutation, cell and biotoxicity. You can minimize problems such as. |